Management
Team

Rémi DANGLA, PhD

CEO, co-founder and inventor of the technology

  • Named as Top 10 Biotech entrepreneur under 30 in 2016 by Labiotech.eu.
  • Named as Top 10 French Innovator Under 35 by MIT Technological Review in 2014.
  • Co-founded Stilla Technologies in 2013 to build a disruptive digital PCR solution, using the microfluidic technologies he helped establish.
  • Started his career in 2009 at the laboratory LadHyx of Ecole Polytechnique, exploring new approaches in droplet microfluidics for easy integration into innovative commercial products.

Khaled BAHI

CFO

  • More than 20 years experience in the medtech industry in Finance and operating roles (Symetis, Fresenius Medical Care, etc.)
  • Joined Stilla® in 2019 to help support the global growth of the company
  • Holds a Master of Science degree in Physics from the ETH Zurich

Ruth SZEBRIES

 General Manager & VP Commercial Operations Americas

  • 34 years of cumulative experience in the “OMICS” market with major Life Science companies (Applied Biosystems, Beckman Coulter, QIAGEN, BGI, etc.)
  • Joined in 2019 to set up the US subsidiary in Beverly MA including direct commercial operations, sales, support, distribution and customer care for the US market.
  • Received her B.S. in Chemistry in Stuttgart Germany with an international UNESCO certification in English, German and Spanish.

Etienne FRADET, PhD

VP of R&D 

  • Joined Stilla® in 2014 as co-founder and used his advanced knowledge about Stilla®’s core technology to design and build Stilla®’s naica® system with his team of engineers.
  • Completed his PhD in fluid mechanics at Ecole Polytechnique.
  • Graduated at Ecole Centrale Paris, and got also a MA degree in Applied Mathematics at Cambridge University.

Quang TRAN

Quality & Regulatory Affairs Director

  • More than 20 years experience in the medtech and Biotech industries in quality, regulatory and operating roles (BioSerenity, Becton Dickinson, Eurobio, etc.)
  • Joined Stilla® in 2019
  • Holds a graduate degree in Biology engineering

Clément GAY

Director of Growth

  • Creates & Make sure that Stilla®’s infrastructure is in place to support high revenue & staff growth
  • Co-founded Stilla® in 2013
  • Graduated from HEC Paris (Major in Entrepreneurship)

Board
members

Nick is the Founding Partner of Illumina Ventures. His passion is building companies at the intersection of technology and human health. Prior to joining the fund, he served as SVP, Corporate & Venture Development for Illumina where he was responsible for strategic planning, business development, licensing, venture investing and acquisitions.

Before joining Illumina, Nick co-founded and was the Executive Chairman of the diagnostics company Quanterix. Previously he was Executive Chairman of True Materials and CEO of ParAllele BioScience, life science tools firms that were both acquired by Affymetrix.

Nick received a B.S. in Engineering from Duke University, was a Winston Churchill Scholar at Cambridge University, and earned a Ph.D. in Electrical Engineering from the University of Maryland.

Rémi co-founded Stilla Technologies in 2013 to build a disruptive digital PCR solution, using the microfluidic technologies he helped establish.

Rémi started his career in 2009 at the laboratory LadHyx of Ecole Polytechnique, exploring new approaches in droplet microfluidics for easy integration into innovative commercial products.

He was named as Top 10 Biotech entrepreneur under 30 in 2016 by Labiotech.eu. and also Top 10 French Innovator Under 35 by MIT Technological Review in 2014.

Khaled has more than 20 years of experience in the medtech industry in Finance and operating roles (Boston Scientific, Symetis, Fresenius Medical Care, etc.) He joined Stilla in 2019 to help support the global growth of the company.

Khaled holds a Master of Science degree in Physics from the ETH Zurich.

Philippe joined Kurma in July 2015. Philippe was previously a Partner with Auriga Partners from 1999 and 2015 and conducted several investments in Life Sciences in Europe and in the USA.

He is also a board member of DNA Script (France), Damae Medical (France), Sensome (France) and Cardiologs (France). Philippe holds a MS in molecular biology (Paris 7 University) and MS in Finance (ESSEC).

Philippe joined the Digital Health venture team of LBO France as a Venture Partner in early 2018 after a distinguished career in healthcare venture capital in the US. He is also part time CEO of a couple biopharmaceutical startups. He started his business career in 1987 in the pharmaceutical industry, with Sandoz Pharmaceutical US affiliate and in 1993 he joined The Boston Consulting Group as a Manager. He has made numerous marquis name investments in the digital health sector over the years (such as ePocrates, Spotfire and Truveris) as part of his broader investments activities, first at The Sprout group which he joined in 1995, and then with New Leaf Venture Partners. In his role of Managing Director he led the spin-off of NLV from Sprout in 2005 and then the fundraising effort of 4 funds totaling over $1billion.

He has investment and board experience across all stage of growth of companies, from start up to public and small buy-outs.

Philippe earned an MDPhD degree from University Paris V and an MBA from Columbia University. He is currently a board member of several private companies in France and the US.

Before joining Tuspark Capital Management Europe and CLIIF fund in Luxembourg as Managing Director, Daniel worked for KPMG Luxembourg from 2014 to 2017.

He has over 20 years of experiences in VC/PE, mezzanine funds, portfolio investments for assets managers, along with the design, management, coordination, implementation and policy advice of UNDP, UNIDO, EU and Asian Development Bank’s development and investment programs.

Daniel holds a PhD in Economics from the University of Copenhagen.